Effect of repeated administration of TRK-820, a κ-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions

Brain Research

Volumn 995, Issue 2, 2004, Pages 167-175

  Suzuki, Tomohiko ^a   Izumimoto, Naoki ^a   Takezawa, Yuko ^a   Fujimura, Morihiro ^a   Togashi, Yuko ^a   Nagase, Hiroshi ^a   Tanaka, Toshiaki ^a   Endoh, Takashi ^a,b  

^a TORAY INDUSTRIES INC   (Japan)

^b NEW ENERGY AND INDUSTRIAL TECHNOLOGY DEVELOPMENT ORGANIZATION   (Japan)

Author keywords

Receptor down regulation; Tolerance; Opioid receptor agonist

Indexed keywords

3,4 DICHLORO N METHYL N [1 PHENYL 2 (1 PYRROLIDINYL)ETHYL]BENZENEACETAMIDE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; MORPHINE; NALFURAFINE; SEDATIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG POTENCY; DRUG TOLERANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TASK PERFORMANCE;

EID: 0346221275     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2003.09.057     Document Type: Article

References (47)

1. Badillo-Martinez D., Kirchgessner A.L., Butler P.D., Bodnar R.J. Monosodium glutamate and analgesia induced by morphine, test-specific effects. Neuropharmacology. 23:1984;1141-1149.
2. Bhargava H.N. Diversity of agents that modify opioid tolerance, physical dependence, abstinence syndrome, and self-administrative behavior. Pharmacol. Rev. 46:1994;293-324.
3. 5]enkephalin on the concentration of cGMP in brain regions and spinal cord of the mouse. Peptides. 18:1997;1629-1634.
4. Bhargava H.N., Ramarao P., Gulati A. Effect of morphine in rats treated chronically with U-50,488H, a κ opioid receptor agonist. Eur. J. Pharmacol. 162:1989;257-264.
5. Bhargava H.N., Thorat S.N. Effect of dizocilpine (MK-801) on analgesia and tolerance induced by U-50,488H, a κ-opioid receptor agonist, in the mouse. Brain Res. 649:1994;111-116.
6. Bhargava H.N., Gulati A., Ramarao P. Effect of chronic administration of U-50,488H, on tolerance to its pharmacological actions and multiple opioid receptors in rat brain regions and spinal cord. J. Pharmacol. Exp. Ther. 251:1989;21-26.
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
8. Costello G.F., Main B.G., Barlow J.J., Carroll J.A., Shaw J.S. A novel series of potent and selective agonists at the opioid κ-receptor. Eur. J. Pharmacol. 151:1988;475-478.
9. Cowan A., Murray C.W. Effect of nor-binaltorphimine on the behavior of mice and rats receiving multiple injections of U-50,488. Prog. Clin. Biol. Res. 328:1990;303-306.
10. Di Chiara G., Imperato A. Opposite effects of μ and κ opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 244:1988;1067-1080.
11. Endoh T., Matsuura H., Tajima A., Izumimoto N., Tajima C., Suzuki T., Saitoh A., Suzuki T., Narita M., Tseng L., Nagase H. Potent antinociceptive effects of TRK-820, a novel κ-opioid receptor agonist. Life Sci. 65:1999;1685-1694.
12. Endoh T., Tajima A., Kamei J., Suzuki T., Narita M., Tseng L., Nagase H. Characterization of the antinociceptive effects of TRK-820 in the rat. Eur. J. Pharmacol. 387:2000;133-140.
13. Endoh T., Tajima A., Izumimoto N., Suzuki T., Saitoh A., Suzuki T., Narita M., Kamei J., Tseng L.F., Mizoguchi H., Nagase H. TRK-820, a selective κ-opioid agonist, produces potent antinociception in cynomolgus monkeys. Jpn. J. Pharmacol. 85:2001;282-290.
14. Feng Y., Narita M., Makimura M., Hoskins B., Ho I.K. Enhancement of the rate of GTP hydrolysis in rat brain by repeated κ-opioid treatment. Brain Res. 667:1994;133-137.
15. Fernandes M., Kluwe S., Coper H. The development of tolerance to morphine in the rat. Psychopharmacology (Berl.). 54:1977;197-201.
16. Finney D.J. Statistical Methods in Biological Assays. 2nd ed. 1964;Hafner Publishing, New York.
17. Fujibayashi K., Sakamoto K., Watanabe M., Iizuka Y. Pharmacological properties of R-84760, a novel κ-opioid receptor agonist. Eur. J. Pharmacol. 261:1994;133-140.
18. He L., Fong J., von Zastrow M., Whistler J.L. Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell. 108:2002;271-282.
19. Ho B.Y., Takemori A.E. Serotonergic involvement in the antinociceptive action of and the development of tolerance to the kappa-opioid receptor agonist, U-50,488H. J. Pharmacol. Exp. Ther. 250:1989;508-514.
20. Jiang Q., Seyed-Mozaffari A., Sebastian A., Archer S., Bidlack J.M. Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism. J. Pharmacol. Exp. Ther. 273:1995;680-688.
21. Kest B., Hopkins E. Morphine tolerance after chronic intracerebroventricular injection in male and female mice. Brain Res. 892:2001;208-210.
22. Kest B., Palmese C., Hopkins E. A comparison of morphine analgesic tolerance in male and female mice. Brain Res. 879:2000;17-22.
23. Kunihara M., Ohyama M., Nakano M., Hayashi S. Analgesic activity of spiradoline mesylate (U-62,066E), a κ opioid agonist in mice. Life Sci. 45:1989;1191-1198.
24. Li J.G., Luo L.Y., Krupnick J.G., Benovic J.L., Liu-Chen L.Y. U50,488H-induced internalization of the human κ opioid receptor involves a beta-arrestin- and dynamin-dependent mechanism. κ Receptor internalization is not required for mitogen-activated protein kinase activation. J. Biol. Chem. 274:1999;12087-12094.
25. Li J.G., Benovic J.L., Liu-Chen L.Y. Mechanisms of agonist-induced down-regulation of the human κ-opioid receptor: internalization is required for down-regulation. Mol. Pharmacol. 58:2000;795-801.
26. Li J.G., Zhang F., Jin X.L., Liu-Chen L.Y. Differential regulation of the human κ opioid receptor by agonists: etorphine and levorphanol reduced dynorphin A- and U50,488H-induced internalization and phosphorylation. J. Pharmacol. Exp. Ther. 305:2003;531-540.
27. Ling G.S., Paul D., Simantov R., Pasternak G.W. Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model. Life Sci. 45:1989;1627-1636.
28. Loh H.H., Smith A.P. Molecular characterization of opioid receptors. Annu. Rev. Pharmacol. Toxicol. 30:1990;123-147.
29. Martin W.R. Pharmacology of opioids. Pharmacol. Rev. 35:1983;283-323.
30. Millan M.J. κ-Opioid receptors and analgesia. Trends Pharmacol. Sci. 11:1990;70-76.
31. Misslin R., Belzung C., Vogel E. Interaction of RO 15-4513 and ethanol on the behaviour of mice: antagonistic or additive effects? Psychopharmacology (Berl.). 94:1988;392-396.
32. Mucha R.F., Kalant H., Linseman M.A. Quantitative relationships among measures of morphine tolerance and physical dependence in the rat. Pharmacol. Biochem. Behav. 10:1979;397-405.
33. Nagase H., Hayakawa J., Kawamura K., Kawai K., Takezawa Y., Matsuura H., Tajima C., Endo T. Discovery of a structurally novel opioid κ-agonist derived from 4,5-epoxymorphinan. Chem. Pharm. Bull. (Tokyo). 46:1998;366-369.
34. Narita M., Makimura M., Feng Y., Hoskins B., Ho I.K. Influence of chronic morphine treatment on protein kinase C activity: comparison with butorphanol and implication for opioid tolerance. Brain Res. 650:1994;175-179.
35. Nestler E.J. Cellular responses to chronic treatment with drugs of abuse. Crit. Rev. Neurobiol. 7:1993;23-39.
36. Patel M.B., Patel C.N., Rajashekara V., Yoburn B.C. Opioid agonists differentially regulate μ-opioid receptors and trafficking proteins in vivo. Mol. Pharmacol. 62:2002;1464-1470.
37. Piercey M.F., Lahti R.A., Schroeder L.A., Einspahr F.J., Barsuhn C. U-50488H, a pure kappa receptor agonist with spinal analgesic loci in the mouse. Life Sci. 31:1982;1197-1200.
38. Seki T., Awamura S., Kimura C., Ide S., Sakano K., Minami M., Nagase H., Satoh M. Pharmacological properties of TRK-820 on cloned μ-, δ- and κ-opioid receptors and nociceptin receptor. Eur. J. Pharmacol. 376:1999;159-167.
39. Smart D., Lambert D.G. The stimulatory effects of opioids and their possible role in the development of tolerance. Trends Pharmacol. Sci. 17:1996;264-269.
40. Stafford K., Gomes A.B., Shen J., Yoburn B.C. μ-Opioid receptor downregulation contributes to opioid tolerance in vivo. Pharmacol. Biochem. Behav. 69:2001;233-237.
41. Thorat S.N., Reddy P.L., Bhargava H.N. Evidence for the role of nitric oxide in κ opiate tolerance in mice. Brain Res. 621:1993;171-174.
42. Togashi Y., Umeuchi H., Okano K., Ando N., Yoshizawa Y., Honda T., Kawamura K., Endoh T., Utsumi J., Kamei J., Tanaka T., Nagase H. Antipruritic activity of the κ-opioid receptor agonist, TRK-820. Eur. J. Pharmacol. 435:2002;259-264.
43. Tsuji M., Yamazaki M., Takeda H., Matsumiya T., Nagase H., Tseng L.F., Narita M., Suzuki T. The novel κ-opioid receptor agonist TRK-820 has no affect on the development of antinociceptive tolerance to morphine in mice. Eur. J. Pharmacol. 394:2000;91-95.
44. Tsuji M., Takeda H., Matsumiya T., Nagase H., Narita M., Suzuki T. The novel κ-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice. Life Sci. 68:2001;1717-1725.
45. VonVoigtlander P.F., Lahti R.A., Ludens J.H. U-50,488H: a selective and structurally novel non-mu-kappa opioid agonist. J. Pharmacol. Exp. Ther. 224:1983;7-12.
46. 3H]-U69,593 binding sites in the rat heart. Life Sci. 50:1992;1143-1148.
47. Yu W., Hao J.X., Xu X.J., Wiesenfeld-Hallin Z. The development of morphine tolerance and dependence in rats with chronic pain. Brain Res. 756:1997;141-146.